BD Expects Alaris Infusion Pump To Return To US Market Next Year
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
You may also be interested in...
Baxter International recorded slight revenue increases during quarter one of 2021, with sales still impacted by COVID-19. Its board remains optimistic , pointing towards new product releases and “operational strength” as redeeming factors.
The US FDA has labeled the recall of nearly 2,500 Alaris Model 8100 infusion pumps as high-risk class I.
Polen led BD’s $24bn acquisition of Bard in 2017 and the $12bn acquisition of CareFusion in 2015. Forlenza has been with BD for almost 40 years, including eight as CEO.